NCT04869488View on ClinicalTrials.gov

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 19, 2021

Primary Completion Date

February 14, 2023

Study Completion Date

February 14, 2023

Conditions

Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG

Fluzoparib

Fluzoparib Orally twice daily（Cohort 1、Cohort 4）

DRUG

Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets

Enzalutamide OR abiraterone acetate Orally once daily（Cohort 1）

DRUG

Fluzoparib Combined With Apatinib

Fluzoparib Orally twice daily; Apatinib Orally once daily（Cohort 2、Cohort 3、Cohort 4）

Trial Locations (1)

200433

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04869488 - A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter